NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Oct 2012
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
6/8 — Strong
MINIVELLE (estradiol) by Noven Pharmaceuticals is estrogen receptor agonists [moa]. Approved for vasomotor symptoms, menopause, hot flashes. First approved in 2012.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MINIVELLE is a transdermal estradiol patch approved in 2012 that delivers estrogen via extended-release film formulation. It treats vasomotor symptoms, menopause, hot flashes, and a broad range of estrogen deficiency-related conditions through estrogen receptor agonism. The product addresses both acute menopausal symptoms and chronic conditions including osteoporosis, endometriosis, and cardiovascular disease prevention.
$0.001BPart D
Peak4.2 years to LOEMINIVELLE is in peak lifecycle stage with modest Part D utilization (3,134 claims in 2023), suggesting a stable but mature commercial position with limited team expansion opportunity.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Indications (3)
Worked on MINIVELLE at Noven Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.